Programmers Hierarchical Interactive Graphics System (PHIGS)

W. T. Hewitt

DOI: https://doi.org/10.1007/978-3-642-46514-7_11

Abstract:

What problem does this paper attempt to address?

A Meta-Analysis of Gemcitabine Containing Chemotherapy for Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Jing Hu,Gang Zhao,Hong-Xia Wang,Lei Tang,Ying-Chun Xu,Yue Ma,Feng-Chun Zhang

DOI: https://doi.org/10.1186/1756-8722-4-11

IF: 28.5

2011-01-01

Journal of Hematology & Oncology

Abstract:BACKGROUND:The objectives of the present study are to investigate the efficacy and safety profile of gemcitabine-based combinations in the treatment of locally advanced and metastatic pancreatic adenocarcinoma (LA/MPC).METHODS:We performed a computerized search using combinations of the following keywords: "chemotherapy", "gemcitabine", "trial", and "pancreatic cancer".RESULTS:Thirty-five trials were included in the present analysis, with a total of 9,979 patients accrued. The analysis showed that the gemcitabine-based combination therapy was associated with significantly better overall survival (OS) (ORs, 1.15; p = 0.011), progression-free survival (PFS) (ORs, 1.27; p < 0.001), and overall response rate (ORR) (ORs, 1.58; p < 0.001) than gemcitabine monotherapy. Similar results were obtained when the gemcitabine-fluoropyrimidine combination was compared with gemcitabine, with the OS (ORs, 1.33; p = 0.007), PFS (ORs, 1.53; p < 0.001), and ORR (ORs 1.47, p = 0.03) being better in the case of the former. The OS (ORs, 1.33; p = 0.019), PFS (ORs, 1.38; p = 0.011), and one-year survival (ORs, 1.40; p = 0.04) achieved with the gemcitabine-oxaliplatin combination were significantly greater than those achieved with gemcitabine alone. However, no survival benefit (OS: ORs, 1.01, p = 0.93; PFS: ORs, 1.19, p = 0.17) was noted when the gemcitabine-cisplatin combination was compared to gemcitabine monotherapy. The combinations of gemcitabine and other cytotoxic agents also afforded disappointing results. Our analysis indicated that the ORR improved when patients were treated with the gemcitabine-camptothecin combination rather than gemcitabine alone (ORs, 2.03; p = 0.003); however, there were no differences in the OS (ORs, 1.03; p = 0.82) and PFS (ORs, 0.97; p = 0.78) in this case.CONCLUSIONS:Gemcitabine in combination with capecitabine or oxaliplatin was associated with enhanced OS and ORR as compared with gemcitabine in monotherapy, which are likely to become the preferred standard first-line treatment of LA/MPC.
Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort

Hongyang Wu,Nana Huang,Chenchen Zhao,Xueyang Hu,Liangshan Da,Wei Huang,Yuanyuan Shen,Fuxing Xiong,Congjun Zhang

DOI: https://doi.org/10.21037/atm-22-544

IF: 3.616

2022-03-01

Annals of Translational Medicine

Abstract:Background: The timely addition of anlotinib to the nab-paclitaxel/gemcitabine regimen may further increase the treatment efficacy for pancreatic adenocarcinoma (PDAC), which has not yet been reported. Therefore, we aimed to compare the efficacy and safety of anlotinib plus nab-paclitaxel/gemcitabine in the first-line treatment of patients with unresectable or metastatic PDAC.Methods: This was a retrospective cohort of patients with unresectable or metastatic PDAC performed in The First Affiliated Hospital of Anhui Medical University from August 17, 2019 to April 3, 2021. Patients who received anlotinib plus nab-paclitaxel/gemcitabine treatment were defined as the anlotinib plus chemotherapy group and patients who received nab-paclitaxel/gemcitabine were defined as the chemotherapy group. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes were the objective response rate (ORR), the disease control rate (DCR), and toxic side effects. Clinical data and follow-up information were mainly obtained from hospital records or by telephone.Results: A total of 33 patients were included in this study, with 17 cases in the anlotinib plus chemotherapy group and 16 cases in the chemotherapy group. The median PFS (mPFS) of the anlotinib plus chemotherapy group was 5 months while the mPFS of the chemotherapy group was 2.7 months (P=0.0220). The median OS (mOS) of the anlotinib plus chemotherapy group was 9 months while the mOS of the chemotherapy group was 6 months (P=0.0060). The 3-month and 6-month PFS, and the 6- and 12-month OS of the anlotinib plus chemotherapy group were significantly higher than those of the chemotherapy group (P<0.05). The proportion of patients with hematological toxicities in the anlotinib plus chemotherapy group was not significantly higher than that in the chemotherapy group.Conclusions: Anlotinib plus nab-paclitaxel/gemcitabine as a first-line treatment regimen is safe and may prolong survival compared with nab-paclitaxel/gemcitabine chemotherapy in patients with unresectable or metastatic PDAC. Randomized controlled trials with large sample sizes are warranted to further evaluate the treatment effects of anlotinib in PDAC.Keywords: Pancreatic adenocarcinoma (PDAC); anlotinib; nab-paclitaxel/gemcitabine; progression-free survival (PFS); overall survival (OS).

oncology,medicine, research & experimental
First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial

Huizi Sha,Fan Tong,Jiayao Ni,Yi Sun,Yahui Zhu,Liang Qi,Xiaoqin Li,Wei Li,Yan Yang,Qing Gu,Xing Zhang,Xiaoxuan Wang,Chan Zhu,Dongsheng Chen,Baorui Liu,Juan Du

DOI: https://doi.org/10.1038/s41392-024-01857-6

IF: 39.3

2024-06-07

Signal Transduction and Targeted Therapy

Abstract:Metastatic pancreatic cancer (mPC) has a dismal prognosis. Herein, we conducted a prospective, multicentre, single-arm, phase II trial evaluating the efficacy and safety of penpulimab and anlotinib in combination with nab-paclitaxel/gemcitabine (PAAG) in patients with first-line mPC (NCT05493995). The primary endpoints included the objective response rate (ORR) and disease control rate (DCR), while secondary endpoints encompassed progression-free survival (PFS), overall survival (OS), and safety. In 66 patients analysed for efficacy, the best response, indicated by the ORR, was recorded at 50.0% (33/66) (95% CI, 37.4–62.6%), with 33 patients achieving partial response (PR). Notably, the DCR was 95.5% (63/66, 95% CI, 87.3–99.1%). The median PFS (mPFS) and OS (mOS) were 8.8 (95% CI, 8.1–11.6), and 13.7 (95% CI, 12.4 to not reached) months, respectively. Grade 3/4 treatment-related adverse events (TRAEs) were reported in 39.4% of patients (26/66). In prespecified exploratory analysis, patients with altered SWI/SNF complex had a poorer PFS. Additionally, low serum CA724 level, high T-cell recruitment, low Th17 cell recruitment, and high NK CD56dim cell scores at baseline were potential predicative biomarkers for more favourable efficacy. In conclusion, PAAG as a first-line therapy demonstrated tolerability with promising clinical efficacy for mPC. The biomolecular findings identified in this study possess the potential to guide the precise clinical application of the triple-combo regimen.

biochemistry & molecular biology,cell biology
Penpulimab Combined with Anlotinib and Nab-Paclitaxel Plus Gemcitabine (PAAG) As First-Line Treatment for Metastatic Pancreatic Cancer: A Prospective, Multicenter, Single-Arm, Phase 2 Study.

Juan Du,Fan Tong,Hui-zi Sha,Yi Sun,Yahui Zhu,Liang Qi,Xiaoqin Li,Wei Li,Yan Yang,Zeqing Li,Caihua Xu,Jiayao Ni,Qing Gu,Xing Zhang,Chan Zhu,Xiaoxuan Wang,Baorui Liu

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.4135

IF: 45.3

2024-01-01

Journal of Clinical Oncology

Abstract:4135 Background: Chemotherapy currently serves as the cornerstone for treating metastatic pancreatic cancer (mPC). Nevertheless, the survival of patients with mPC remains poor. Besides, the efficacy of single-agent immune checkpoint inhibitors or antiangiogenesis in the treatment of mPC is not satisfying. Therefore, it is important to explore combination therapy options for patients with mPC. This trial was conducted to evaluate the effectiveness and safety of penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) for mPC. Methods: This was a prospective, multicenter, single-arm phase II trial. Eligible pts were those who aged over 18 years, histologically or cytologically confirmed PC, have not received treatment before and radiographically showed distant metastases and measurable lesions. Patients received penpulimab (200mg, IV, D1) and Anlotinib (12mg, P.O, QD, D1-14), in addition to nab-paclitaxel (125mg/m2, I.V, D1,8) and gemcitabine (1.0g/m2, I.V, D1,8), administered over a 21-day treatment cycle. The primary endpoint was objective response rate (ORR) and disease control rate (DCR). Secondary end points included Progression-free Survival (PFS), overall survival (OS) and safety. Immune microenvironmental features of baseline were analyzed as exploratory results (NCT05493995). Results: 66 pts were enrolled and received PAAG therapy, and the last follow-up time was December 31, 2023. All pts were eligible for response evaluation. The ORR was recorded at 50% (33/66) (95% CI, 37.4%-62.6%), with 33 pts achieving partial response. The DCR was 95.5% (63/66) (95% CI, 87.3%-99.1%). With median follow-up duration of 12.8 months, median PFS was 8.8 months (95% CI, 8.1–11.3) and median OS was 13.7 months (95% CI, 12.4-not reached). The most common TRAEs were anaemia, leukocytopenia, fatigue and rash. Grade 3 TRAEs were reported in 36.4% pts (24/66). In exploratory analysis, higher T cell recruiting score and lower baseline serum CA72-4 level were detected in PR pts compared with SD/PD pts. Furthermore, the B cell, NK CD56dim cell and Th9 cell scores were up-regulated in PFS-long pts. Conclusions: PAAG regimen as first-line treatment was demonstrated to be tolerable, with promising anti-tumor activity in mPC. The identified biomolecular markers revealed potential to guide precision treatment of PAAG for mPC. Clinical trial information: NCT05493995 .
Efficacy of nab‐paclitaxel vs. Gemcitabine in combination with S‐1 for advanced pancreatic cancer: A multicenter phase II randomized trial

Xi Guo,Wenhui Lou,Yaolin Xu,Rongyuan Zhuang,Lie Yao,Junwei Wu,Deliang Fu,Jun Zhang,Jing Liu,Yefei Rong,Dayong Jin,Wenchuan Wu,Xuefeng Xu,Yuan Ji,Lili Wu,Minzhi Lv,Xiuzhong Yao,Xiaowei Liu,Dansong Wang,Tiantao Kuang,Liang Liu,Wenquan Wang,Tianshu Liu,Yuhong Zhou

DOI: https://doi.org/10.3892/ol.2024.14293

2024-02-20

Oncology Letters

Abstract:Patients with advanced pancreatic cancer (PC) need a cost‐effective treatment regimen. The present study was designed to compare the efficacy and safety of nab‐paclitaxel plus S‐1 (AS) and gemcitabine plus S‐1 (GS) regimens in patients with chemotherapy‐naïve advanced PC. In this open‐label, multicenter, randomized study named AvGmPC, eligible patients with chemotherapy‐naïve advanced PC were randomly assigned (1:1) to receive AS (125 mg/m 2 nab‐paclitaxel, days 1 and 8; 80‐120 mg S‐1, days 1‐14) or GS (1,000 mg/m 2 gemcitabine, days 1 and 8; 80‐120 mg S‐1, days 1‐14). The treatment was administered every 3 weeks until intolerable toxicity or disease progression occurred. The primary endpoint was progression‐free survival (PFS). Between December 2018 and March 2022, 101 of 106 randomized patients were treated and evaluated for analysis (AS, n=49; GS, n=52). As of the data cutoff, the median follow‐up time was 11.37 months [95% confidence interval (CI), 9.31‐13.24]. The median PFS was 7.16 months (95% CI, 5.19‐12.32) for patients treated with AS and 6.41 months (95% CI, 3.72‐8.84) for patients treated with GS (HR=0.78; 95% CI, 0.51‐1.21; P=0.264). The AS regimen showed a slightly improved overall survival (OS; 13.27 vs. 10.64 months) and a significantly improved ORR (44.90 vs. 15.38%; P=0.001) compared with the GS regimen. In the subgroup analyses, PFS and OS benefits were observed in patients treated with the AS regimen who had KRAS gene mutations and high C‐reactive protein (CRP) levels (≥5 mg/l). The most common grade ≥3 adverse events were neutropenia, anemia and alopecia in the two groups. Thrombocytopenia occurred more frequently in the GS group than in the AS group. While the study did not meet the primary endpoint, the response benefit observed for AS may be suggestive of meaningful clinical activity in this population. In particular, promising survival benefits were observed in the subsets of patients with KRAS gene mutations and high CRP levels, which is encouraging and warrants further investigation. This trial was retrospectively registered as ChiCTR1900024588 on July 18, 2019.

oncology
Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis.

Yiyin Zhang,Jin Xu,Jie Hua,Jiang Liu,Chen Liang,Qingcai Meng,Quanxing Ni,Si Shi,Xianjun Yu

DOI: https://doi.org/10.7150/jca.29898

IF: 3.9

2019-01-01

Journal of Cancer

Abstract:To evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NG) as a first-line treatment for advanced pancreatic cancer. A meta-analysis was performed to assess the impact on the objective response rate (ORR), survival rate and grade 3/4 adverse events. Of the 2,056 patients included from 26 studies, the median overall survival ranged from 6.9 months to 24.7 months, with a 1-year survival rate of 45.2% (95%CI: 35.8% - 54.5%). The 6-month progression-free survival rate was 41.0% (95%CI: 30.5% - 51.4%), and the ORR was 31.6% (95%CI: 26.7% - 36.6%). Fifty locally advanced pancreatic cancer (LAPC) patients underwent surgery and had an R0 resection rate of 52.0%. No death was caused by toxicity, and 1,329 grade 3/4 adverse events were reported in 1,353 patients. NG has been proven to reduce tumours with an acceptable toxicity profile in metastatic pancreatic cancer. This analysis further demonstrates the efficacy and safety of NG for treating LAPC.
The Multicenter, Phase Ii Prospective Study of Paclitaxel Plus Capecitabine As First-Line Chemotherapy in Advanced Gastric Carcinoma

Jifang Gong,Bing Hu,Xiaotian Zhang,Fengchun Zhang,Jun Zhang,Nong e Xu,Qingxia Fan,Yuxian Bai,Shunchang Jiao,Jinwan Wang,Chunmei Bai,Leizhen Zheng,Yingqiang Shi,Yunpeng Liu,Jun Liang,Guoqing Hu,Ying Cheng,Ruihua Xu,Yu Bai,Lin Shen

DOI: https://doi.org/10.1634/theoncologist.2013-0137

2014-01-01

Abstract:Background. The efficacy and toxicity of paclitaxel plus capecitabine (PX) as first-line treatment in advanced gastric cancer (AGC) was evaluated.Methods. Patients with previously untreated AGC were included. PX was given every 3 weeks until a maximum of six cycles or progression. Capecitabine monotherapy was continued for patients without disease progression. The primary endpoint was progression-free survival, and secondary endpoints were objective response rate, overall survival (OS), and safety.Results. Overall, 194 patients were treated per protocol and one patient was excluded because of allergy to paclitaxel. Response was evaluated in 175 patients, with an objective response rate of 34.8%. After a median follow-up of 33.2 months, disease progression was observed in 141 patients, 137 died, and 16 were lost to follow-up, with progression-free survival of 188 days and OS of 354 days. In multivariate Cox regression analysis, no factor remained an independent predictor of OS. Forty-five patients who received capecitabine monotherapy after PX had longer OS (531 days). Adverse events were mild (Fig. 1), and the most common grade 3-4 toxicities were leucopenia and neutropenia.Conclusion. PX as a first-line treatment has promising efficacy in AGC. Based on these data, a phase III study has been launched for further investigation.
Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma

Yuan Zong,Zhi Peng,Xicheng Wang,Ming Lu,Lin Shen,Jun Zhou

DOI: https://doi.org/10.2147/CMAR.S263773

2020-01-01

Cancer Management and Research

Abstract:Objective: Nab-paclitaxel plus gemcitabine (nab-P/G) has been established as a standard first-line treatment in metastatic pancreatic ductal adenocarcinoma (PDAC). S-1, as an oral fluoropyrimidine derivative, demonstrated effective for PDAC. This study aimed to evaluate the efficacy and safety of first-line chemotherapy with nab-paclitaxel plus S-1 (nab-P/S) versus nab-P/G in patients with advanced PDAC. Methods: Patients with advanced PDAC receiving nab-P/S (n = 65) or nab-P/G (n = 45) as first-line chemotherapy between November 2013 and June 2019 were reviewed. Results: The objective response rate (ORR) and disease control rate were numerically higher with nab-P/S than with nab-P/G (38.5% vs 28.9%, P = 0.30, 73.8% vs 66.7%, P = 0.42, respectively). ORRs of the primary lesion were similar for both groups (30.8% and 22.2%, P = 0.32). The median progression-free survival and overall survival were comparable between the two groups (5.5 vs 5.7 months, P = 0.34, 10.2 vs 11.3 months, P = 0.74, respectively). Nab-P/S was associated with a numerically lower risk of adverse events, especially hematologic adverse events. Conclusion: Nab-P/S could be a convenient alternative with similar efficacy and a favorable safety profile compared with nab-P/G as first-line chemotherapy for advanced PDAC, as well as an option for neoadjuvant therapy.
Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study

Zhitao Chen,Yahui He,Chenchen Ding,Jun Chen,Yangjun Gu,Min Xiao,Qiyong Li

DOI: https://doi.org/10.2147/OTT.S427942

IF: 4

2023-01-01

OncoTargets and Therapy

Abstract:Background: Pancreatic cancer is a deadly disease with a low five years survival rate, and chemotherapy remains the standard treatment for advanced cases. However, the efficacy of chemotherapy alone is limited, and there is a need for new treatment options. Recently, immune checkpoint inhibitors (ICIs), particularly programmed death-1 (PD-1) inhibitors, have shown promising results in various cancers, including pancreatic cancer. In this study, we explore the safety and efficacy of PD-1 inhibitors in combination with chemotherapy for advanced pancreatic cancer.Materials and methods: A retrospective analysis was conducted on clinical data from 27 patients with advanced pancreatic cancer who were administered a combination of anti-PD-1 antibody and gemcitabine plus nab-paclitaxel (GnP) regimen. The study evaluated the safety of the treatment as well as the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).Results: In this study, treatment with a combination of anti-PD-1 antibody and GnP regimen for pancreatic cancer resulted in partial response (PR) for 10 out of 27 (37.04%) patients, stable disease (SD) for 10 (37.04%) patients, and progressive disease (PD) for 7 (25.92%) patients. The study found that the median OS (mOS) for these patients was 16.4 months [standard error (SE) = 1.117, 95% confidence interval (CI) 14.211-18.589], while the median PFS (mPFS) was 6.4 months (SE = 1.217, 95% CI 3.981-8.752). Subgroup analysis revealed that pancreatic cancer patients' Eastern Cooperative Oncology Group (ECOG) performance status (PS) (0 vs 1) and treatment cycles (<= 6 cycles vs >6 cycles) significantly affected OS and PFS. Patients experienced mostly grade 1-2 adverse events (AEs), which were relieved through clinical treatment.Conclusion: The combination of GnP with anti-PD-1 antibodies shows promise as a potential treatment option for advanced pancreatic cancer.
Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

Gang Jin,Shiwei Guo,Yanqiao Zhang,Yue Ma,Xiaodong Guo,Xiaocui Zhou,Qin Yu

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.4138

IF: 45.3

2021-05-20

Journal of Clinical Oncology

Abstract:4138 Background: Pancreatic ductal adenocarcinoma(PDAC)is one of the most lethal malignancies worldwide and is characterized by extremely poor prognosis. Nab-paclitaxel plus gemcitabine has been recommended by international guidelines for first-line treatment of advanced PDAC but chemoresistance is difficult to avoid. Combination of immune checkpoint inhibitors (ICIs) and chemotherapy has demonstrated substantial promise for the treatment of several advanced malignancies. A few recent studies have begun to explore the effect of ICIs monotherapy or co in advanced PDAC with few meaningful results. KN046, a novel recombinant humanized bispecific antibody, can simultaneously block PD-1/PD-L1 and CTLA-4 pathways and restore T-cell immune response to tumor. The purpose of this study is to evaluate the efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic PDAC. Methods: This ongoing phase II trial in China enrolled pts with histologically or cytologically confirmed unresectable locally advanced or metastatic PDAC who have ECOG PS of 0-1 and never received systemic anti-tumor therapy for advanced or metastatic diseases. KN046 (5mpk, Q2W) plus nab-paclitaxel (125mg/m 2 , D1, 8, 15, Q4W) and gemcitabine (1000mg/m 2 , D1, 8, 15, Q4W) were administered 4-6 cycles followed by KN046 (5mpk) maintenance therapy every 2 weeks. Tumour response was assessed according to RECIST 1.1 every 8 weeks. The primary endpoint is investigator-assessed ORR. Secondary endpoints are DCR, DOR, TTP, PFS, OS and safety. Results: As of December 15, 2020, 17 pts were enrolled, median (range) age was 56 (36-75) years, 9 pts ECOG 1, and 7 pts had liver metastases. Median KN046 exposure time was 9.5 wks. 9 pts were included in the efficacy analysis and 17 pts in the safety analysis. In best overall response assessment, there were 55.6% PR (5/9) and 33.3% SD (3/9). ORR was 55.6% (95% CI: 21.2̃86.3), and DCR was 88.9% (95% CI: 51.8̃99.7). The overall incidence of KN046 related treatment-emergent adverse events was 64.7%, with 29.4% were grade 3 TRAE. The most common KN046 related treatment-emergent adverse events (≥10%) were alanine aminotransferase increased (n = 5, 29.4%), nausea (n = 3, 17.6%), rash (n = 3, 17.6%), aspartate aminotransferase increased (n = 2, 11.8%), diarrhoea (n = 2, 11.8%), hyperphosphataemia (n = 2, 11.8%), pyrexia (n = 2, 11.8%), vomiting (n = 2, 11.8%). Conclusions: Combining KN046 with nab-paclitaxel and gemcitabine as first-line treatment for unresectable locally advanced or metastatic PDAC patients is safe and feasible, and lays the foundation for subsequent clinical trials. Clinical trial information: NCT04324307.

oncology
Low-dose Nab-Paclitaxel-based Combination Chemotherapy in Heavily-Pretreated Pancreatic or Ampullary Cancer Patients: Taiwanese Single-Center Case Series.

Shih-Hung Yang,Jhe-Cyuan Guo,Chiun Hsu,Chih-Hung Hsu,Sung Hsin Kuo,Ann-Lii Cheng,Kun-Huei Yeh

DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.e15695

IF: 45.3

2016-01-01

Journal of Clinical Oncology

Abstract:e15695 Background: In heavily-pretreated periampullary cancer patients, the prognosis remains poor, and no standard salvage therapy exists. Methods: Pancreatic or ampullary cancer patients who had been treated with nab-paclitaxel (Nab-P) for palliation after failure of gemcitabine and/or fluoropyrimidines were retrospectively reviewed at National Taiwan University Hospital among Year 2013-2015. Results: Thirty-nine patients were identified (M/F: 27/12; median age of years: 64, range 24-86; pancreas/ampulla: 36/3). Initial stage was I, II, III, IV in 1, 20, 3, and 15 patients, respectively. Twenty-one patients had received curative surgery. Median recurrence-free survival was 3.2 (95% CI: 2.7-3.7) months. Adjuvant therapy had been given in 16 patients. Median prior lines of treatment were 2 (range 1-6). Nineteen (49%) patients had ECOG performance status ≥ 2. Best response to prior therapy was complete or partial response (PR) in 6 patients and stable disease (SD) in 8 patients. Namely, the Nab-P-based regimens included Nab-P/gemcitabine (Nab-PG, N = 27), Nab-P/platinum/5-FU analogs (Nab-PPF, N = 7), Nab-P/5-FU analogs (N = 3), Nab-P/gemcitabine/S-1 (N = 1), and Nab-P/irinotecan/5-FU (Nab-PIF, N = 1). The median dose of nab-paclitaxel was 65 (range 51-128) mg/m2/dose with the schedule of D1/15, D1/8, and D1/8/15 in 22, 14, and 3 patients, respectively. One PR and four SD were observed with Nab-PG, one SD with Nab-PPF, and one SD with Nab-PIF. Progressive disease was observed in 22 patients; 10 patients were not evaluable. Median progression-free survival was 2.6 (95% CI: 2.1-3.0) months. Median overall survival was 5.1 (95% CI: 4.4-5.9) months. Hematological toxicities were significant with ≥ Gr3 leucopenia and/or neutropenia in 4 patients, and anemia in 5 patients. Granulocyte-colony stimulating factor was used in 21 patients for prophylaxis or rescue. Significant ( ≥ Gr3) non-hematological toxicities except infection (N = 7) were not frequent. Conclusions: In heavily-pretreated periampullary cancer patients, combination chemotherapy with relatively low doses of Nab-P is fairly tolerable with modest efficacy.
Floating volumetric image formation using a dihedral corner reflector array device.

D. Miyazaki,N. Hirano,Yuki Maeda,S. Yamamoto,T. Mukai,S. Maekawa

DOI: https://doi.org/10.1364/AO.52.00A281

IF: 1.9

Applied Optics

Abstract:A volumetric display system using an optical imaging device consisting of numerous dihedral corner reflectors placed perpendicular to the surface of a metal plate is proposed. Image formation by the dihedral corner reflector array (DCRA) is free from distortion and focal length. In the proposed volumetric display system, a two-dimensional real image is moved by a mirror scanner to scan a three-dimensional (3D) space. Cross-sectional images of a 3D object are displayed in accordance with the position of the image plane. A volumetric image is observed as a stack of the cross-sectional images. The use of the DCRA brings compact system configuration and volumetric real image generation with very low distortion. An experimental volumetric display system including a DCRA, a galvanometer mirror, and a digital micro-mirror device was constructed to verify the proposed method. A volumetric image consisting of 1024×768×400 voxels was formed by the experimental system.
Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer

Yaolin Xu,Xi Guo,Yue Fan,Dansong Wang,Wenchuan Wu,Lili Wu,Tianshu Liu,Bei Xu,Yi Feng,Yan Wang,Wenhui Lou,Yuhong Zhou

DOI: https://doi.org/10.1093/jjco/hyy063

2018-06-01

Abstract:Objective: To compare efficacy and safety of nabpaclitaxel plus S-1 (AS) with gemcitabine plus S-1 (GS) as first-line treatment for metastatic pancreatic cancer. Methods: We conducted a retrospective cohort, single-institution analysis by reviewing medical records of 38 patients who received either AS (nabpaclitaxel 125 mg/m2 on Days 1, 8 and S-1 80 mg/m2 on Days 1 to 14) or GS (gemcitabine 1000 mg/m2 on Days 1, 8 and S-1 80 mg/m2 on Days 1 to 14) chemotherapy. Results: AS was associated with a prolonged median time to progression (TTP; 7.1 months, 95% CI, 4.5-9.7 vs. 3.6 months, 95% CI, 1.8-5.4; P value = 0.022) and improved median overall survival (OS; 10.2 months, 95% CI, 9.1-11.3 vs. 6 months, 95% CI, 4.2-7.8; P value <0.001) compared with GS. In cox proportional hazards model, treatment regimen was the only variable to be significantly associated with improvements in both TTP and OS. Subgroup analyses based on HER2 expression showed that AS seemed to have better outcome of OS in HER2 positive patients (HR = 0.168; 95% CI, 0.022-1.27; P value = 0.084). Hematological adverse events were commonly seen in both group (12.5% and 22.7%, GS and AS group, Grade 3 or 4; P value = 0.675) while AS got increased risk of sensory neuropathy (6 of 22 patients in AS, 27.3% vs. 0 of 16 patients in GS, all grade; P value = 0.03). Conclusions: AS could be an effective treatment regimen for metastatic pancreatic cancer under surveillance of toxicity.
Efficacy observation of albumin-bound paclitaxel plus gemcitabine for the treatment of advanced pancreatic cancer

Chao SONG,Yi FENG,Yue FAN,Hong CHEN,Dansong WANG,Yuhong ZHOU,Wenhui LOU

2016-01-01

Abstract:Objective To evaluate the efficacy and safety of albumin-bound paclitaxel plus gemcitabine for the treatment of advanced pancreatic cancer patients in Chinese. Methods From March 2012 to January 2015, 27 patients with advanced pancreatic cancer diagnosed by pathology were assigned to receive albumin-bound paclitaxel plus gemcitabine as first-line therapy. Albumin-bound paclitaxel was administered at a dose of 125 mg/m2 plus gemcitabine 1000 mg/m2 on day 1 and 8 of a 21-day cycle. Response to chem-otherapy was assessed by RECIST criteria 1. 1 and toxicity was evaluated according to National Cancer Institute Common Toxicity Crite-ria 3. 0. The clinical follow-up data from chemotherapy were investigated for comparison of median progression-free survival( PFS) and overall survival( OS) between different clinicopathologic characteristics. Results All patients were available for evaluation. None got complete response, 2 cases had partial response and 19 cases had stable disease. The response rate( RR) was 7. 4% and the disease control rate(DCR) was 77. 8%. Of the 27 patients, the median PFS was 5. 0(95%CI:4. 0-6. 7) months and the median OS was 8. 0 (95%CI:7. 5-13. 8) months. The number of chemotherapy cycles were correlated with PFS and OS in pooled treatment arm analyses. The main adverse reactions were nausea and vomiting( 48. 1%) , fatigue( 55. 5%) , fever( 7. 4%) , rash itching( 3. 7%) and peripheral nerve abnormalities( 11. 1%) . The major adverse reactions were mainly bone marrow suppression. Among them, grade 3-4 hematologic toxicity included white blood cell reduction, thrombocytopenia and hemoglobin reduction. Conclusion The combination of albumin-bound paclitaxel and gemcitabine is effective and tolerated in the treatment of advanced pancreatic cancer patients in Chinese.
Efficacy and Safety of Nab-Paclitaxel Plus Gemcitabine in the Treatment of Advanced Pancreatic Cancer by Transcatheter Arterial Chemotherapy

Y. Hua,Z. Ning,L. Xu,Y. Li,P. Wang,H. Chen,Z. Chen,Z. Meng

DOI: https://doi.org/10.1016/j.hpb.2020.11.585

IF: 3.842

2021-01-01

HPB

Abstract:Objective: To evaluate the efficacy and safety of Nab-paclitaxel combined with gemcitabine (AG) regimen in the treatment of advanced pancreatic cancer by transcatheter arterial chemotherapy/chemoembolization (TAC/TACE). Method: Retrospective analysis of 72 advanced pancreatic cancer patients who were treated at Fudan University Shanghai Cancer Center from 2016 to 2018. The TAC regimen consisted of Nab-paclitaxell 125mg/m2 combined with gemcitabine hydrochloride 1000mg/m2, perfusion 10 minutes, pancreatic head and neck tumor perfused through the gastroduodenal artery. If accompanied by liver metastasis, embolization was implemented. Result: Among the 72 patients, 8 patients received treatment once, 11 patients received treatment twice, 14 patients received treatment three times, and 39 patients received treatment more than four times with an interval of 21～45 days. The survival rates of 1-year and 2-year were 36.11% and 8.33%. respectively. Median survival time was 8.77 months. The PFS rates of 3-month and 6-month were 72.22% and 45.83% respectively. Multivariate analysis showed that KPS ≥ 80, III stage was associated with longer survival, and that surgery and TAC/TACE treatment suggested a good prognostic factor. The median progression-free survival time was 4.5 months. Treatment-related grade III and above hematologic adverse reactions and non-hematologic adverse reactions were decreased compared with intravenous chemotherapy. All adverse reactions improved after treatment, and there were no treatment-related deaths. Conclusions: Nab-paclitaxell combined with Gemcitabine has better safety in the treatment of pancreatic cancer by transarterial infusion chemotherapy. Compared with intravenous chemotherapy, Nab-paclitaxell combined with gemcitabine can reduce the adverse reactions, effectively control the disease and prolong patients´ survival.
Genomic Biomarker Discovery of First-Line Gemcitabine/nabpaclitaxel Treatment in Chinese Advanced Pancreatic Carcinoma Patients.

Du Juan,Pan Qiuyue,Sha Huizi,Zou Zhengyun,Kong Weiwei,Qiu Xin,Lu Changchang,Zhang Xin,Liu Baorui

DOI: https://doi.org/10.1200/jco.2021.39.3_suppl.436

IF: 45.3

2021-01-01

Journal of Clinical Oncology

Abstract:436 Background: Pancreatic carcinoma is one of the most lethal malignancies worldwide and is characterized by extremely poor prognosis. Gemcitabine plus Nab-paclitaxel (GNp) has been recommended by international guidelines for first-line treatment of locally advanced or metastatic pancreatic carcinoma. However, exploration into molecular biomarkers of GNp treatment is still limited. This study aims to observe and evaluate the efficacy and safety of first-line GNp treatment of pancreatic carcinoma, and to explore potential predictive and prognostic biomarkers to screen advantageous population. Methods: From December 20, 2018 to July 6, 2020, patients with metastatic pancreatic carcinoma, who received first-line GNp treatment, were enrolled. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), overall response rate (ORR), disease control rate (DCR), and adverse events (AE). Patients were collected formalin fixed paraffin embedded (FFPE) samples and sequenced by a next-generation sequencing (NGS)-based 450 gene panel carried out by OrigiMed, a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Results: In this study, tissue samples from 101 patients were assessed by NGS, including 58 (57.4%) primary tissues and 43 (42.6%) metastasis tissues. So far, 72 patients were available for efficacy analysis, the ORR and DCR were 38.2% and 77.9%, respectively, and were similar between patients sampled from primary lesions and metastasis lesions. The PFS and OS were 176 days and 308 days, respectively. The most frequently mutated genes were KRAS (91.9%), TP53 (76.8%), CDKN2A (32.3%) and SMAD4 (26.3%). Germline pathogenic BRCA2 mutations were detected in 3 (3.0%) patients, while somatic mutations of BRCA2 were found in 2 (2.0%) patients. For KRAS, missense mutations resulted in single amino acid substitutions primarily at G12 (88.1%), and lower frequencies at Q61 (4.0%) and V14 (1.0%). At G12, five different amino acid substitutions have been identified, with G12D (37.6%) the predominant mutation, G12V (32.7%), G12R (11.9%), G12C (3.0%) and G12A (1.0%). The ORR to AG treatment was significantly higher in TP53-alteration (-alt, 47.1%) than in TP53-wild-type (-WT, 11.1%) subgroups (p=0.01). Median OS times in CDKN2B-alt and CDKN2B-WT patients were 180 days and 323 days (p=0.029), respectively. Conclusions: Current evidence indicates that GNp is a valuable option for the first-line treatment of metastatic pancreatic cancer. TP53 may serve as a novel response-predictive gene for GNp treatment in pancreatic carcinoma. Overall survival was significantly prolonged in CDKN2B-WT patients compared with CDKN2B-alt patients. This study provided insights in identifying patients who might potentially benefit from GNp therapy. Clinical trial information: NCT03768687.
Nab-paclitaxel Plus S-1 Versus Nab-Paclitaxel Plus Gemcitabine As First-Line Chemotherapy in Patients with Advanced Pancreatic Ductal Adenocarcinoma: a Randomized Study

Zong Yuan,Yuan Jiajia,Peng Zhi,Lu Ming,Wang Xicheng,Shen Lin,Zhou Jun

DOI: https://doi.org/10.1007/s00432-020-03442-0

2020-01-01

Journal of Cancer Research and Clinical Oncology

Abstract:To investigate the efficacy and safety of nab-paclitaxel plus S-1 (nab-P/S) versus nab-paclitaxel plus gemcitabine (nab-P/G) as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC). Treatment-naïve patients with advanced PDAC were equally randomized to receive nab-P/S or nab-P/G. The primary endpoint was the objective response rate (ORR). The secondary endpoints were ORR of the primary lesion, disease control rate, progression-free survival (PFS), overall survival (OS) and safety. The trial was registered at https://clinicaltrials.gov as NCT03636308. A total of 110 patients were planned for enrollment, but the trial was prematurely closed because no better ORR was observed with nab-P/S among the first 40 patients assigned between 08/2018 and 06/2019. The ORR was numerically higher with nab-P/S versus nab-P/G (35.0% vs 25.0%, P = 0.49). The ORRs of the primary lesion for both arms were similar (30.0% and 25.0%, P = 0.72). Disease control rate was 70.0% in each arm. There was no significant difference in PFS and OS between the two arms (median PFS, 6.3 vs 5.7 months, P = 0.34; median OS, 10.2 vs 10.2 months, P = 0.92). Risks of hematological toxicity, liver injury and rash were significantly decreased in the nab-P/S arm. A biweekly combination of nab-P/S yielded comparable efficacy with nab-P/G but improved safety profile. It may be a promising and convenient alternative as first-line and neoadjuvant settings for advanced PDAC.
Efficacy and safety of nab-paclitaxel plus S-1(nab-P/S-1) versus nab-paclitaxel plus gemcitabine (nab-P/Gem) for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): A randomized study

Yuan Zong,Zhi Peng,Xicheng Wang,Lin Shen,Jun Zhou

DOI: https://doi.org/10.1200/jco.2020.38.4_suppl.717

IF: 45.3

2020-01-01

Journal of Clinical Oncology

Abstract:717 Background: Nab-P/Gem significantly improved survival compared with gem in patients (pts) with metastatic PDAC, but the ORR was limited to 23% with increased myelosuppression. Two phase II trials demonstrated high ORR of 50.0-53.1% with nab-P/S-1 and showed less hematologic toxicity. Methods: A randomized (1:1) phase II trial was conducted. Eligibility required treatment-naïve pts with unresectable PDAC. Pts received nab-P 125mg/m2on day 1 + S-1 80-120mg orally per day on day 1-7 every 2 weeks or nab-P 125mg/m2+ Gem 1000mg/m2 on days 1,8 every 3 weeks. With an increase of ORR from 25% to 50%, 100 pts were required for 90% power at a two-sided significance level of 0.05. We enrolled 40 pts for a pilot study. Primary endpoints were ORR and 6-month PFS rate. Secondary endpoints were ORR of primary lesion, DCR, PFS, OS and safety. Results: 40 pts were enrolled between 06/2018 and 06/2019, including locally advanced (27.5%) and metastatic (72.5%) PDACs. 42.5% were male and the median age was 61 (range, 36-75) years old. The median duration of treatment was 2.3 months in nab-P/S-1 (n = 20) and 2.7 months in nab-P/Gem (n = 20). In the intention-to-treat (ITT) population, the ORR and DCR were 35.0% vs 25.0% ( P= 0.49) and 70.0% vs 70.0%, respectively.The ORR of primary lesion was 30.0% vs 25.0% ( P= 0.72). In the evaluable pts (nab-P/S-1 n = 18, nab-P/Gem n = 18), the ORR, DCR and the ORR of primary lesion were 38.9% vs 27.8%, 77.8% vs 77.8% and 35.3% vs 29.4%, respectively.With the median follow-up of 5.0 (range 0.3-11.4) months, the median PFS and 6-month PFS rate was 6.3 vs 5.7 months and 56.1% vs 36.2%( P= 0.61) for nab-P/S-1 and nab-P/Gem, respectively. The median OS have not reached. Grade 3/4 toxicities occurred in 30.0% nab-P/S-1 and 30.0% nab-P/Gem: leukopenia/neutropenia(15.0% vs 25.0%), febrile neutropenia (0 vs 5.0%), rash (0 vs 5.0%) and diarrhea (10.0% vs 0). Conclusions: Compared with nab-P/Gem, nab-P/S-1 had higher ORR, ORR of primary lesion and longer PFS without significant difference. Nab-P/S-1 developed a trend towards less hematologic toxicity. Follow up for survival is ongoing. Clinical trial information: 03636308.
Nab-paclitaxel/S-1(AS) Versus Nab-Paclitaxel/gemcitabine(ag) for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma (apdac): A Retrospective Analysis of Efficacy and Safety.

Yuan Zong,Zhi Peng,Ming Lu,Xicheng Wang,Jun Zhou,Lin Shen

DOI: https://doi.org/10.1200/jco.2019.37.15_suppl.e15743

IF: 45.3

2019-01-01

Journal of Clinical Oncology

Abstract:e15743 Background: AG significantly improved PFS and OS compared with gemcitabine monotherapy in patients (pts) with metastatic PDAC, but the confirmed ORR was limited to 23% with increased grade 3 or 4 myelosuppression. In GEST and JASPAC01 studies, S-1 showed non-inferior or superior activity to gemcitabine in advanced and postoperative PDAC. S-1 also developed less hematologic adverse events especially in neutropenia and was a convenient oral alternative. Two single-arm phase II trials in China demonstrated high ORR of 50.0-53.1% with AS. We investigated the efficacy and safety of first-line chemotherapy with AS versus AG in pts with aPDAC. Methods: A retrospective review was conducted of aPDAC pts treated with first-line AS and AG in GI dpt. Of PUCH between 11/2013 and 12/2018. Pts received 125mg/m2 nab-paclitaxel intravenously (IV) on day1, and 80-100mg S-1 orally per day on day1-7 every two weeks in AS cohort, while pts received 125mg/m2 nab-paclitaxel IV on day1,8, and 1000mg/m2 gemcitabine IV on day1,8 every three weeks in AG cohort. ORR, ORR of primary lesion, DCR, PFS, OS and safety were analysed between two cohorts. Survival outcomes were evaluated by Kaplan-Meier method and compared with the log-rank test. A Cox proportional hazard model was made to determine independent predictors of survival. Results: A total of 70 pts (45 in AS cohort, 25 in AG cohort) with locally advanced (4%) and metastatic (96%) PDACs were identified. 75% were male and the median age was 65(range 36-72). Among intention-to-treat population, the ORR and DCR were 40.0% vs 32.0% (p = 0.70) and 75.6% vs 64.0% (p = 0.57) in AS and AG cohort, respectively. The ORR of primary lesion was 31.1% with AS vs 20.0% with AG (p = 0.73). With the median follow-up of 9.8 months(range 2.3-22.2), the median PFS and OS were 4.7m vs 6.7m (HR, 1.2; 95% CI, 0.6 to 2.4; p = 0.62) and 10.3m vs 11.3m (HR, 0.9; 95% CI, 0.5 to 1.8; p = 0.78) in AS and AG cohort, respectively. Grade 3/4 toxicities occurred in 31.1% AS vs 36.0% AG (p = 0.59). Most G3/4 toxicities were: leukopenia/neutropenia (26.7% vs 20.0%), febrile neutropenia (2.2% vs 8.0%), thrombocytopenia (0 vs 12%), fatigue (4.4% vs 12%), peripheral neuropathy (0 vs 8.0%). In multivariate analysis, liver metastasis was the only independent predictor of poor OS (HR 0.3, 95%CI 0.1-0.8, p = 0.014). Conclusions: AS was a comparable and convenient alternative with manageable toxicities in aPDAC. There was a trend towards improved ORR of primary lesion compared with AG.
French Keller Hansel and the history of allergy.

G. Shambaugh

DOI: https://doi.org/10.1001/ARCHOTOL.1983.00800160060015

1983-02-01

A M A Archives of Otolaryngology

Abstract:The death of French Keller Hansel, MD, at the age of 88 years, on Aug 29, 1981, brought to an end the career of a great man and an exciting era in our specialty of otolaryngology. A brilliant scientist and an enterprising innovator, Hansel was born in 1893, in Fidelity, Ill. He graduated from the St Louis School of Medicine and served as an intern and medical resident at the Missouri Baptist Hospital, St Louis. In 1921, he went to the Mayo Clinic, Rochester, Minn, first in the field of surgical pathology and then as a Fellow in otolaryngology under H. I. Lillie, MD. His examination of pathologic sections from surgical specimens called to the attention of his inquiring mind the unusual eosinophilic infiltration of the subepithelial tissues of numerous specimens of nasal and sinus mucosa removed at surgery on the nose and nasal accessory sinuses. He used these observations,

Programmers Hierarchical Interactive Graphics System (PHIGS)

A Meta-Analysis of Gemcitabine Containing Chemotherapy for Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort

First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial

Penpulimab Combined with Anlotinib and Nab-Paclitaxel Plus Gemcitabine (PAAG) As First-Line Treatment for Metastatic Pancreatic Cancer: A Prospective, Multicenter, Single-Arm, Phase 2 Study.

Efficacy of nab‐paclitaxel vs. Gemcitabine in combination with S‐1 for advanced pancreatic cancer: A multicenter phase II randomized trial

Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis.

The Multicenter, Phase Ii Prospective Study of Paclitaxel Plus Capecitabine As First-Line Chemotherapy in Advanced Gastric Carcinoma

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma

Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study

Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

Low-dose Nab-Paclitaxel-based Combination Chemotherapy in Heavily-Pretreated Pancreatic or Ampullary Cancer Patients: Taiwanese Single-Center Case Series.

Floating volumetric image formation using a dihedral corner reflector array device.

Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer

Efficacy observation of albumin-bound paclitaxel plus gemcitabine for the treatment of advanced pancreatic cancer

Efficacy and Safety of Nab-Paclitaxel Plus Gemcitabine in the Treatment of Advanced Pancreatic Cancer by Transcatheter Arterial Chemotherapy

Genomic Biomarker Discovery of First-Line Gemcitabine/nabpaclitaxel Treatment in Chinese Advanced Pancreatic Carcinoma Patients.

Nab-paclitaxel Plus S-1 Versus Nab-Paclitaxel Plus Gemcitabine As First-Line Chemotherapy in Patients with Advanced Pancreatic Ductal Adenocarcinoma: a Randomized Study

Efficacy and safety of nab-paclitaxel plus S-1(nab-P/S-1) versus nab-paclitaxel plus gemcitabine (nab-P/Gem) for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): A randomized study

Nab-paclitaxel/S-1(AS) Versus Nab-Paclitaxel/gemcitabine(ag) for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma (apdac): A Retrospective Analysis of Efficacy and Safety.

French Keller Hansel and the history of allergy.